MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC

This study is a single-arm, open-label, multi-cohort, single-center phase II clinical trial designed to observe and evaluate the efficacy and safety of MRG003 (a EGFR-ADC) in combination with pucotenlimab (a PD-1 inhibitor) for the treatment of EGFR-positive unresectable recurrent or metastatic ATC/PDTC. All patients will receive the combination therapy every three weeks until disease progression or other event as defined in the protocol occurs.

Trial Details

NCT ID
NCT07235566
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • MRG003 in combination with pucotenlimab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the protocol requirements.
  • Age ≥18 years on the day of signing the informed consent form, regardless of gender.
  • Expected survival time ≥12 weeks.
  • Patients with pathologically confirmed EGFR-positive ATC or PDTC, currently in a recurrent or metastatic stage and not eligible for curative resect…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →